Trypanosoma brucei

Last updated

Trypanosoma brucei
Tb brucei.jpg
T. b. brucei TREU667 (Bloodstream form, phase-contrast picture. Black bar indicates 10 µm.)
Scientific classification Red Pencil Icon.png
Domain: Eukaryota
Phylum: Euglenozoa
Class: Kinetoplastea
Order: Trypanosomatida
Family: Trypanosomatidae
Genus: Trypanosoma
T. brucei
Binomial name
Trypanosoma brucei
Plimmer & Bradford, 1899
  • Trypanosoma brucei brucei
  • Trypanosoma brucei gambiense
  • Trypanosoma brucei rhodesiense

Trypanosoma brucei is a species of parasitic kinetoplastid belonging to the genus Trypanosoma . This parasite is the cause of vector-borne diseases of vertebrate animals, including humans, carried by species of tsetse fly in sub-Saharan Africa. In humans T. brucei causes African trypanosomiasis, or sleeping sickness. In animals it causes animal trypanosomiasis, also called nagana in cattle and horses. [1] T. brucei has traditionally been grouped into three subspecies: T. b. brucei, T. b. gambiense and T. b. rhodesiense. [2] The first is a parasite of non-human vertebrates, while the latter two are known to be parasites of humans. Only rarely can the T. b. brucei infect a human. [3]


T. brucei is transmitted between mammal hosts by an insect vector belonging to different species of tsetse fly (Glossina). Transmission occurs by biting during the insect's blood meal. The parasites undergo complex morphological changes as they move between insect and mammal over the course of their life cycle. The mammalian bloodstream forms are notable for their cell surface proteins, variant surface glycoproteins, which undergo remarkable antigenic variation, enabling persistent evasion of host adaptive immunity leading to chronic infection. T. brucei is one of only a few pathogens known to cross the blood brain barrier. [4] There is an urgent need for the development of new drug therapies, as current treatments can have severe side effects and can prove fatal to the patient. [5]

Whilst not historically regarded as T. brucei subspecies due to their different means of transmission, clinical presentation, and loss of kinetoplast DNA, genetic analyses reveal that T. equiperdum and T. evansi are evolved from parasites very similar to T. b. brucei, and are thought to be members of the brucei clade. [6]

The parasite was discovered in 1894 by Sir David Bruce, after whom the scientific name was given in 1899. [7] [8]

History and discovery

Sleeping sickness in animals were described in ancient Egyptian writings. During the Middle Ages, Arabian traders noted the prevalence of sleeping sickness among Africans and their dogs. [9] It was a major infectious diseases in southern and eastern Africa in the 19th century. [10] The Zulu Kingdom (now part of South Africa) was severely struck by the disease, which became known to the British as nagana , [1] a Zulu word for to be low or depressed in spirit. In other parts of Africa, Europeans called it the "fly disease." [11] [12]

A man having sleeping sickness at Buruma Island, Uganda. An inhabitant of Buruma Island, Uganda, suffering from sleep Wellcome V0029100.jpg
A man having sleeping sickness at Buruma Island, Uganda.

John Aktins, an English naval surgeon, gave first medical description of human sleeping sickness in 1734. He attributed deaths which he called "sleepy distemper" in Guinea to the infection. [13] Another English physician Thomas Masterman Winterbottom gave clearer description of the symptoms from Sierra Leone in 1803. [14] Winterbottom described a key feature of the disease as swollen posterior cervical lymph nodes and slaves who developed such swellings were ruled unfit for trade. [13] The symptom is eponymously known as "Winterbottom's sign." [15]

The Royal Army Medical Corps appointed David Bruce, who at the time was assistant professor of pathology at the Army Medical School in Netley, in 1894 to investigate the disease in South Africa. On 27 October 1894, Bruce and his microbiologist-wife Mary Elizabeth Bruce (née Steele) moved to Ubombo Hill, where the disease was most prevalent. [16] He soon discovered protozoan parasites from the blood of infected animals. It was the discovery of Trypanosoma brucei, [17] the name created by British zoologists Henry George Plimmer and John Rose Bradford in 1899 in honour of the discoverer. [18] The genus Trypanosoma was already introduced by Hungarian physician David Gruby in his description of T. sanguinis, a species he discovered in frogs in 1843. [19]

British Colonial Surgeon Robert Michael Forde was the first to find the parasite in human. He found it from an English steamboat captain who was admitted to a hospital at Bathurst, Gambiaex, in 1901. [20] His report in 1902 indicates that he believed it to be a kind of parasitic worm (helminth). [21] From the same person, Forde's colleague Joseph Everett Dutton identified it as a protozoan belonging to the genus Trypanosoma. Knowing the distinct features, Dutton proposed a new species name in 1902:

At present then it is impossible to decide definitely as to the species, but if on further study it should be found to differ from other disease-producing trypanosomes I would suggest that it be called Trypanosoma gambiense. [22]

In Uganda, the first case of human infection was reported in 1898. [10] It was followed by an outbreak in 1900. [23] By 1901, it became severe with death toll estimated to about 20,000. [24] More than 250,000 people died in the epidemic that lasted for two decades. [23] The disease commonly popularised as "negro lethargy." [25] [26] It was not known whether the human sleeping sickness and nagana were similar or the two disease were caused by similar parasites. [27] Even the observations of Forde and Dutton did not indicate that the trypanosome was related to sleeping sickness. [28]

The Royal Society constituted a three-member Sleeping Sickness Commission on 10 May 1902 to investigate the epidemic in Uganda. [29] The Commission comprised George Carmichael Low from the London School of Hygiene and Tropical Medicine as the leader, his colleague Aldo Castellani and Cuthbert Christy, a medical officer on duty in Bombay, India. [30] [31] At the time, a debate remained on the etiology, some favoured bacterial infection while some believed as helminth infection. [32] The first investigation focussed on Filaria perstans (later renamed Mansonella perstans ), a small roundworm transmitted by flies, and bacteria as possible causes, only to discover that the epidemic was not related to these pathogens. [33] [34] The team was described as an "ill-assorted group" [35] and a "queer lot", [36] and the expedition "a failure." [37] Low, whose conduct was described as "truculent and prone to take offence," left the Commission and Africa after three months. [38]

In February 1902, the British War Office, following a request from the Royal Society, appointed David Bruce to lead the second Sleeping Sickness Commission. [39] With David Nunes Nabarro (from the University College Hospital), Bruce and his wife joined Castellani and Christy on 16 March. [40] In November 1902, Castellani had found the trypanosomes in the cerebrospinal fluid of an infected person. He was convinced that the trypanosome was the causative parasite of sleeping sickness. Like Low, his conduct has been criticised and the Royal Society refused to publish his report. He was further infuriated when Bruce advised him not to make rash conclusion without further evidences, as there were many other parasites to consider. [41] Castellani left Africa in April and published his report as "On the discovery of a species of Trypanosoma in the cerebrospinal fluid of cases of sleeping sickness" in The Lancet. [42] By then the Royal Society had already published the report. [43] By August 1903, Bruce and his team established that the disease was transmitted the tsetse fly, Glossina palpalis. [44] However, Bruce did not understand the trypanosoma life cycle and believed that the parasites were simply transmitted from one person to another. [9]

Around the same time, Germany sent a expeditionary team led by Robert Koch to investigate the epidemic in Togo and East Africa. In 1909, one of the team members, Friedrich Karl Kleine discovered that the parasite had developmental stages in the tsetse flies. [45] Bruce, in the third Sleeping Sickness Commission (1908–1912) that included Albert Ernest Hamerton, H.R. Bateman and Frederick Percival Mackie, established the complete developmental stages of the trypanosome in tsetse fly. [46] [47]

Another human trypanosome (now called T. brucei rhodesiense) was discovered by British parasitologists John William Watson Stephens and Harold Benjamin Fantham. [45] In 1910, Stephens noted in his experimental infection in rats that the trypanosome, obtained from an individual from Rhodesia, was not the same as T. gambiense. Fantham described the morphology and found that it was a different trypanosome. [48] [49]


T. brucei is a species complex that includes:


False colour SEM micrograph of the procyclic form of T. brucei as found in the tsetse fly midgut. The cell body is shown in orange and the flagellum is in red. 84 pixels/mm. TrypanosomaBrucei ProcyclicTrypomastigote SEM.jpg
False colour SEM micrograph of the procyclic form of T. brucei as found in the tsetse fly midgut. The cell body is shown in orange and the flagellum is in red. 84 pixels/μm.

T. brucei is a typical unicellular eukaryotic cell, and measures 8 to 50 μm in length. It has an elongated body having a streamlined and tapered shape. Its cell membrane (called pellicle) encloses the cell organelles, including the nucleus, mitochondria, endoplasmic reticulum, Golgi apparatus, and ribosomes. In addition, there is an unusual organelle called the kinetoplast, which is a complex of thousands of mitochondria. [56] The kinetoplast lies near the basal body with which it is indistinguishable under microscope. From the basal body arises a single flagellum that run towards the anterior end. Along the body surface, the flagellum is attached to the cell membrane forming an undulating membrane. Only the tip of the flagellum is free at the anterior end. [57] The cell surface of the bloodstream form features a dense coat of variant surface glycoproteins (VSGs) which is replaced by an equally dense coat of procyclins when the parasite differentiates into the procyclic phase in the tsetse fly midgut. [58]

The six main morphologies of trypanosomatids. The different life cycle stages of T brucei fall into the trypomastigote and epimastigote morphological categories. TrypanosomatidMorphologies PlainSVG.svg
The six main morphologies of trypanosomatids. The different life cycle stages of T brucei fall into the trypomastigote and epimastigote morphological categories.

Trypanosomatids show several different classes of cellular organisation of which two are adopted by Trypanosoma brucei at different stages of the life cycle: [57]

T. brucei flagellar structure Trypanosome Flagellum Structure.png
T. brucei flagellar structure

These names are derived from the Greek mastig- meaning whip, referring to the trypanosome's whip-like flagellum. The trypanosome flagellum has two main structures. It is made up of a typical flagellar axoneme, which lies parallel to the paraflagellar rod, [59] a lattice structure of proteins unique to the kinetoplastids, euglenoids and dinoflagellates. [60] [61]

The microtubules of the flagellar axoneme lie in the normal 9+2 arrangement, orientated with the + at the anterior end and the − in the basal body. The cytoskeletal structure extends from the basal body to the kinetoplast. The flagellum is bound to the cytoskeleton of the main cell body by four specialised microtubules, which run parallel and in the same direction to the flagellar tubulin. [62] [63]

The flagellar function is twofold — locomotion via oscillations along the attached flagellum and cell body, [64] [65] and attachment to the fly gut during the procyclic phase.[ citation needed ]

Life cycle

Life cycle Trypanosoma brucei Life Cycle.svg
Life cycle

T. brucei completes its life cycle between tsetse fly (of the genus Glossina) and mammalian hosts, including humans, cattle, horses, and wild animals. In stressful environments, T. brucei produces exosomes containing the spliced leader RNA and uses the endosomal sorting complexes required for transport (ESCRT) system to secrete them as extracellular vesicles. [66] When absorbed by other trypanosomes these EVs cause repulsive movement away from the area and so away from bad environments. [66]

In mammalian host

Infection occurs when a vector tsetse fly bites a mammalian host. The fly injects the metacyclic trypomastigotes into the skin tissue. The trypomastigotes enter the lymphatic system and into the bloodstream. The initial trypomastigotes are short and stumpy (SS). Once inside the bloodstream, they grow into long and slender forms (LS). Then, they multiply by binary fission. Some of the daughter cells then become short and stumpy again. [67] [68] [69] [1] The long slender forms are able to penetrate the blood vessel endothelium and invade extravascular tissues, including the central nervous system (CNS). [64]

Sometimes, wild animals can be infected by the tsetse fly and they act as reservoirs. In these animals, they do not produce the disease, but the live parasite can be transmitted back to the normal hosts. [67] Besides preparation to be taken up and vectored to another host by a tsetse fly, transition from LS to SS in the mammal serves to prolong the host's lifespan controlling parasitemia aids in increasing the total transmitting duration of any particular infested host. [69] [1]

In tsetse fly

The short and stumpy trypomastigotes (SS) are taken up by tsetse flies during a blood meal. [69] [1] Survival in the tsetse midgut is one reason for the particular adaptations of the SS stage. [69] [1] The trypomastigotes enter the midgut of the fly where they become procyclic trypomastigotes. Because the fly faces digestive damage from immune factors in the bloodmeal, it produces serpins to suppress them - and Ooi et al 2015 found T. brucei in turn hijacks these serpins. T. brucei hijacks GmmSRPN3 , GmmSRPN5 , GmmSRPN9 , and especially GmmSRPN10 to aid its own midgut infection, using them to inactivate bloodmeal trypanolytic factors which would otherwise make the fly host inhospitable. [70] :346 These rapidly divide to become epimastigotes. The epimastigotes migrate from the gut via the proventriculus to the salivary glands where they get attached to the salivary gland epithelium. In the salivary glands, some parasites detach and undergo transformation into short and stumpy trypomastigotes. These become the infective metacyclic trypomastigotes. They are injected into the mammalian host along with the saliva on biting. Complete development in the fly takes about 20 days. [67] [68]

In the case of T. b. brucei infecting G. p. gambiensis, during this time the parasite changes the proteome contents of the fly's head. This may be the reason/a reason for the behavioral changes seen, especially the unnecessarily increased feeding frequency, which increases transmission opportunities. This may be due in part to the altered glucose metabolism observed, causing a perceived need for more calories. (The metabolic change, in turn, being due to complete absence of glucose-6-phosphate 1-dehydrogenase in infected flies.) Monoamine neurotransmitter synthesis is also altered: Production of aromatic L-amino acid decarboxylase - involved in dopamine and serotonin synthesis - and α-methyldopa hypersensitive protein was induced. This is very similar to the alterations in other dipteran vectors' head proteomes under infection by other eukaryotic parasites of mammals, found in another study by the same team in the same year. [71]


Binary fission

Trypanosome cell cycle (procyclic form) Trypanosome Cell Cycle.png
Trypanosome cell cycle (procyclic form)

The reproduction of T. brucei is unusual compared to most eukaryotes. The nuclear membrane remains intact and the chromosomes do not condense during mitosis. The basal body, unlike the centrosome of most eukaryotic cells, does not play a role in the organisation of the spindle and instead is involved in division of the kinetoplast. The events of reproduction are: [57]

  1. The basal body duplicates and both remain associated with the kinetoplast. Each basal body forms a separate flagellum.
  2. Kinetoplast DNA undergoes synthesis then the kinetoplast divides coupled with separation of the two basal bodies.
  3. Nuclear DNA undergoes synthesis while a new flagellum extends from the younger, more posterior, basal body.
  4. The nucleus undergoes mitosis.
  5. Cytokinesis progresses from the anterior to posterior.
  6. Division completes with abscission.


In the 1980s, DNA analyses of the developmental stages of T. brucei started to indicate that the trypomastigote in the tsetse fly undergoes meiosis, i.e., a sexual reproduction stage. [72] But it is not always necessary for a complete life cycle. [73] The existence of meiosis-specific proteins was reported in 2011. [74] The haploid gametes (daughter cells produced after meiosis) were discovered in 2014. The haploid trypomastigote-like gametes can interact with each other via their flagella and undergo cell fusion (the process is called syngamy). [75] [76] Thus, in addition to binary fission, T. brucei can multiply by sexual reproduction. Trypanosomes belong to the supergroup Excavata and are one of the earliest diverging lineages among eukaryotes. [77] The discovery of sexual reproduction in T. brucei supports the hypothesis that meiosis and sexual reproduction are ancestral and ubiquitous features of eukaryotes. [78]

Infection and pathogenicity

The insect vectors for T. brucei are different species of tsetse fly (genus Glossina). The major vectors of T. b. gambiense, causing West African sleeping sickness, are G. palpalis, G. tachinoides, and G. fuscipes. While the principal vectors of T. b. rhodesiense, causing East African sleeping sickness, are G. morsitans, G. pallidipes, and G. swynnertoni. Animal trypanosomiasis is transmitted by a dozen species of Glossina. [79]

In later stages of a T. brucei infection of a mammalian host the parasite may migrate from the bloodstream to also infect the lymph and cerebrospinal fluids. It is under this tissue invasion that the parasites produce the sleeping sickness. [67]

In addition to the major form of transmission via the tsetse fly, T. brucei may be transferred between mammals via bodily fluid exchange, such as by blood transfusion or sexual contact, although this is thought to be rare. [80] [81]


Some phytochemicals have shown research promise against the T. b. brucei strain. [82] Aderbauer et al., 2008 and Umar et al., 2010 find Khaya senegalensis is effective in vitro and Ibrahim et al., 2013 and 2008 in vivo (in rats). [82] Ibrahim et al., 2013 find a lower dose reduces parasitemia by this subspecies and a higher dose is curative and prevents injury. [82]


Koppen-Geiger Map Africa present.svg
T. brucei is only found in the blue areas

T. brucei is found where its tsetse fly vectors are prevalent in continental Africa. That is to say, tropical rainforest (Af), tropical monsoon (Am), and tropical savannah (Aw) areas of continental Africa. [57] Hence, the equatorial region of Africa is called the "sleeping sickness" belt. However, the specific type of the trypanosome differs according to geography. T. b. rhodesiense is found primarily in East Africa (Botswana, Democratic Republic of the Congo, Ethiopia, Kenya, Malawi, Tanzania, Uganda and Zimbabwe), while T. b. gambiense is found in Central and West Africa.


T. brucei is a major cause of livestock disease in sub-Saharan Africa. [1] [83] It is thus of tremendous veterinary concern and one of the greatest limitations on agriculture in Africa and the economic life of sub-Saharan Africa. [1] [83]


Trypanosoma brucei gambiense evolved from a single progenitor ~10,000 years ago. [84] It is evolving asexually and its genome shows the Meselson effect. [84]


There are two subpopulations of T. b. gambiense that possesses two distinct groups that differ in genotype and phenotype. Group 2 is more akin to T. b. brucei than group 1 T. b. gambiense. [85]

All T. b. gambiense are resistant to killing by a serum component — trypanosome lytic factor (TLF) of which there are two types: TLF-1 and TLF-2. Group 1 T. b. gambiense parasites avoid uptake of the TLF particles while those of group 2 are able to either neutralize or compensate for the effects of TLF. [86]

In contrast, resistance in T. b. rhodesiense is dependent upon the expression of a serum resistance associated (SRA) gene. [87] This gene is not found in T. b. gambiense. [88]


The genome of T. brucei is made up of: [89]

Most genes are held on the large chromosomes, with the minichromosomes carrying only VSG genes. The genome has been sequenced and is available on GeneDB. [90]

The mitochondrial genome is found condensed into the kinetoplast, an unusual feature unique to the kinetoplastid protozoans. The kinetoplast and the basal body of the flagellum are strongly associated via a cytoskeletal structure [91]

In 1993, a new base, ß-d-glucopyranosyloxymethyluracil (base J), was identified in the nuclear DNA of T. brucei. [92]

VSG coat

The surface of T. brucei and other species of trypanosomes is covered by a dense external coat called variant surface glycoprotein (VSG). [93] VSGs are 60-kDa proteins which are densely packed (~5 x 106 molecules) to form a 12–15 nm surface coat. VSG dimers make up about 90% of all cell surface proteins in trypanosomes. They also make up ~10% of total cell protein. For this reason, these proteins are highly immunogenic and an immune response raised against a specific VSG coat will rapidly kill trypanosomes expressing this variant. However, with each cell division there is a possibility that the progeny will switch expression to change the VSG that is being expressed. [94] [95]

This VSG coat enables an infecting T. brucei population to persistently evade the host's immune system, allowing chronic infection. VSG is highly immunogenic, and an immune response raised against a specific VSG coat rapidly kills trypanosomes expressing this variant. Antibody-mediated trypanosome killing can also be observed in vitro by a complement-mediated lysis assay. However, with each cell division there is a possibility that one or both of the progeny will switch expression to change the VSG that is being expressed. The frequency of VSG switching has been measured to be approximately 0.1% per division. [96] As T. brucei populations can peak at a size of 1011 within a host [97] this rapid rate of switching ensures that the parasite population is typically highly diverse. [98] [99] Because host immunity against a specific VSG does not develop immediately, some parasites will have switched to an antigenically-distinct VSG variant, and can go on to multiply and continue the infection. The clinical effect of this cycle is successive 'waves' of parasitemia (trypanosomes in the blood). [93]

Expression of VSG genes occurs through a number of mechanisms yet to be fully understood. [100] The expressed VSG can be switched either by activating a different expression site (and thus changing to express the VSG in that site), or by changing the VSG gene in the active site to a different variant. The genome contains many hundreds if not thousands of VSG genes, both on minichromosomes and in repeated sections ('arrays') in the interior of the chromosomes. These are transcriptionally silent, typically with omitted sections or premature stop codons, but are important in the evolution of new VSG genes. It is estimated up to 10% of the T. brucei genome may be made up of VSG genes or pseudogenes. It is thought that any of these genes can be moved into the active site by recombination for expression. [95] VSG silencing is largely due to the effects of histone variants H3.V and H4.V. These histones cause changes in the three-dimensional structure of the T. brucei genome that results in a lack of expression. VSG genes are typically located in the subtelomeric regions of the chromosomes, which makes it easier for them to be silenced when they are not being used. [101] [102] It remains unproven whether the regulation of VSG switching is purely stochastic or whether environmental stimuli affect switching frequency. Lythgoe et al 2007 presents the best fitting known model, attributing switching to only two factors: Variation in activation of individual VSG genes; and differentiation to the "short stumpy" stage - triggered by conditions of high population density - which is the nonreproductive, interhost transmission stage. [70] As of 2021 it also remains unexplained how this transition is timed and how the next surface protein gene is chosen. [1] These questions of antigenic variation in T. brucei and other parasites are among the most interesting in the field of infection. [1]

Killing by human serum and resistance to human serum killing

Trypanosoma brucei brucei (as well as related species T. equiperdum and T. evansi ) is not human infective because it is susceptible to innate immune system 'trypanolytic' factors present in the serum of some primates, including humans. These trypanolytic factors have been identified as two serum complexes designated trypanolytic factors (TLF-1 and −2) both of which contain haptoglobin related protein (HPR) and apolipoprotein LI (ApoL1). TLF-1 is a member of the high density lipoprotein family of particles while TLF-2 is a related high molecular weight serum protein binding complex. [103] [104] The protein components of TLF-1 are haptoglobin related protein (HPR), apolipoprotein L-1 (apoL-1) and apolipoprotein A-1 (apoA-1). These three proteins are colocalized within spherical particles containing phospholipids and cholesterol. The protein components of TLF-2 include IgM and apolipoprotein A-I. [105]

Trypanolytic factors are found only in a few species, including humans, gorillas, mandrills, baboons and sooty mangabeys. This appears to be because haptoglobin-related protein and apolipoprotein L-1 are unique to primates. This suggests these genes originated in the primate genome 25  million years ago- 35  million years ago. [106]

Human infective subspecies T. b. gambiense and T. b. rhodesiense have evolved mechanisms of resisting the trypanolytic factors, described below.


ApoL1 is a member of a six gene family, ApoL1-6, that have arisen by tandem duplication. These proteins are normally involved in host apoptosis or autophagic death and possess a Bcl-2 homology domain 3. [107] ApoL1 has been identified as the toxic component involved in trypanolysis. [108] ApoLs have been subject to recent selective evolution possibly related to resistance to pathogens. [109]

The gene encoding ApoL1 is found on the long arm of chromosome 22 (22q12.3). Variants of this gene, termed G1 and G2, provide protection against T. b. rhodesiense. [110] These benefits are not without their downside as a specific ApoL1 glomerulopathy has been identified. [110] [111] This glomerulopathy may help to explain the greater prevalence of hypertension in African populations. [112]

The gene encodes a protein of 383 residues, including a typical signal peptide of 12 amino acids. [113] The plasma protein is a single chain polypeptide with an apparent molecular mass of 42 kiloDaltons. ApoL1 has a membrane pore forming domain functionally similar to that of bacterial colicins. [114] This domain is flanked by the membrane addressing domain and both these domains are required for parasite killing.

Within the kidney, ApoL1 is found in the podocytes in the glomeruli, the proximal tubular epithelium and the arteriolar endothelium. [115] It has a high affinity for phosphatidic acid and cardiolipin and can be induced by interferon gamma and tumor necrosis factor alpha. [116]


Hpr is 91% identical to haptoglobin (Hp), an abundant acute phase serum protein, which possesses a high affinity for hemoglobin (Hb). When Hb is released from erythrocytes undergoing intravascular hemolysis Hp forms a complex with the Hb and these are removed from circulation by the CD163 scavenger receptor. In contrast to Hp–Hb, the Hpr–Hb complex does not bind CD163 and the Hpr serum concentration appears to be unaffected by hemolysis. [117]

Killing mechanism

The association of HPR with hemoglobin allows TLF-1 binding and uptake via the trypanosome haptoglobin-hemoglobin receptor (TbHpHbR). [118] TLF-2 enters trypanosomes independently of TbHpHbR. [118] TLF-1 uptake increases when haptoglobin level is low. TLF-1 overtakes haptoglobin and binds free hemoglobin in the serum. However the complete absence of haptoglobin is associated with a decreased killing rate by serum. [119]

The trypanosome haptoglobin-hemoglobin receptor is an elongated three a-helical bundle with a small membrane distal head. [120] This protein extends above the variant surface glycoprotein layer that surrounds the parasite.

The first step in the killing mechanism is the binding of TLF to high affinity receptors—the haptoglobin-hemoglobin receptors—that are located in the flagellar pocket of the parasite. [118] [121] The bound TLF is endocytosed via coated vesicles and then trafficked to the parasite lysosomes. ApoL1 is the main lethal factor in the TLFs and kills trypanosomes after insertion into endosomal / lysosomal membranes. [108] After ingestion by the parasite, the TLF-1 particle is trafficked to the lysosome wherein ApoL1 is activated by a pH mediated conformational change. After fusion with the lysosome the pH drops from ~7 to ~5. This induces a conformational change in the ApoL1 membrane addressing domain which in turn causes a salt bridge linked hinge to open. This releases ApoL1 from the HDL particle to insert in the lysosomal membrane. The ApoL1 protein then creates anionic pores in the membrane which leads to depolarization of the membrane, a continuous influx of chloride and subsequent osmotic swelling of the lysosome. This influx in its turn leads to rupture of the lysosome and the subsequent death of the parasite. [122]

Resistance mechanisms: T. b. gambiense

Trypanosoma brucei gambiense causes 97% of human cases of sleeping sickness. Resistance to ApoL1 is principally mediated by the hydrophobic β-sheet of the T. b. gambiense specific glycoprotein. [123] Other factors involved in resistance appear to be a change in the cysteine protease activity and TbHpHbR inactivation due to a leucine to serine substitution (L210S) at codon 210. [123] This is due to a thymidine to cytosine mutation at the second codon position. [124]

These mutations may have evolved due to the coexistence of malaria where this parasite is found. [123] Haptoglobin levels are low in malaria because of the hemolysis that occurs with the release of the merozoites into the blood. The rupture of the erythrocytes results in the release of free haem into the blood where it is bound by haptoglobin. The haem is then removed along with the bound haptoglobin from the blood by the reticuloendothelial system. [125]

Resistance mechanisms: T. b. rhodesiense

Trypanosoma brucei rhodesiense relies on a different mechanism of resistance: the serum resistance associated protein (SRA). The SRA gene is a truncated version of the major and variable surface antigen of the parasite, the variant surface glycoprotein. [126] However, it has little similarity (low sequence homology) with the VSG gene (<25%). SRA is an expression site associated gene in T. b. rhodesiense and is located upstream of the VSGs in the active telomeric expression site. [127] The protein is largely localized to small cytoplasmic vesicles between the flagellar pocket and the nucleus. In T. b. rhodesiense the TLF is directed to SRA containing endosomes while some dispute remains as to its presence in the lysosome. [108] [128] SRA binds to ApoL1 using a coiled–coiled interaction at the ApoL1 SRA interacting domain while within the trypanosome lysosome. [108] This interaction prevents the release of the ApoL1 protein and the subsequent lysis of the lysosome and death of the parasite.

Baboons are known to be resistant to Trypanosoma brucei rhodesiense. The baboon version of the ApoL1 gene differs from the human gene in a number of respects including two critical lysines near the C terminus that are necessary and sufficient to prevent baboon ApoL1 binding to SRA. [129] Experimental mutations allowing ApoL1 to be protected from neutralization by SRA have been shown capable of conferring trypanolytic activity on T. b. rhodesiense. [87] These mutations resemble those found in baboons, but also resemble natural mutations conferring protection of humans against T. b. rhodesiense which are linked to kidney disease. [110]

See also

Related Research Articles

African trypanosomiasis Parasitic disease

African trypanosomiasis, also known as African sleeping sickness or simply sleeping sickness, is an insect-borne parasitic infection of humans and other animals. It is caused by the species Trypanosoma brucei. Humans are infected by two types, Trypanosoma brucei gambiense (TbG) and Trypanosoma brucei rhodesiense (TbR). TbG causes over 98% of reported cases. Both are usually transmitted by the bite of an infected tsetse fly and are most common in rural areas.

Trypanosomatida Order of flagellate protists in the kinetoplastid excavates

Trypanosomatida is a group of kinetoplastid excavates distinguished by having only a single flagellum. The name is derived from the Greek trypano (borer) and soma (body) because of the corkscrew-like motion of some trypanosomatid species. All members are exclusively parasitic, found primarily in insects. A few genera have life-cycles involving a secondary host, which may be a vertebrate, invertebrate or plant. These include several species that cause major diseases in humans. Trypanosomatida are intracellular parasites.

Tsetse fly Genus of disease-spreading insects

Tsetse, sometimes spelled tzetze and also known as tik-tik flies, are large biting flies that inhabit much of tropical Africa. Tsetse flies include all the species in the genus Glossina, which are placed in their own family, Glossinidae. The tsetse are obligate parasites that live by feeding on the blood of vertebrate animals. Tsetse have been extensively studied because of their role in transmitting disease. They have a prominent economic impact in sub-Saharan Africa as the biological vectors of trypanosomes, which cause human sleeping sickness and animal trypanosomiasis. Tsetse are multivoltine and long-lived, typically producing about four broods per year, and up to 31 broods over their lifespans.

Trypanosomiasis Medical condition

Trypanosomiasis or trypanosomosis is the name of several diseases in vertebrates caused by parasitic protozoan trypanosomes of the genus Trypanosoma. In humans this includes African trypanosomiasis and Chagas disease. A number of other diseases occur in other animals.

Suramin Medical drug

Suramin is a medication used to treat African sleeping sickness and river blindness. It is the treatment of choice for sleeping sickness without central nervous system involvement. It is given by injection into a vein.

<i>Trypanosoma</i> Genus of parasitic flagellate protist in the Kinetoplastea class

Trypanosoma is a genus of kinetoplastids, a monophyletic group of unicellular parasitic flagellate protozoa. Trypanosoma is part of the phylum Sarcomastigophora. The name is derived from the Greek trypano- (borer) and soma (body) because of their corkscrew-like motion. Most trypanosomes are heteroxenous and most are transmitted via a vector. The majority of species are transmitted by blood-feeding invertebrates, but there are different mechanisms among the varying species. Some, such as Trypanosoma equiperdum, are spread by direct contact. In an invertebrate host they are generally found in the intestine, but normally occupy the bloodstream or an intracellular environment in the vertebrate host.


Melarsoprol is an arsenic-containing medication used for the treatment of sleeping sickness. It is specifically used for second-stage disease caused by Trypanosoma brucei rhodesiense when the central nervous system is involved. For Trypanosoma brucei gambiense, eflornithine or fexinidazole is usually preferred. It is effective in about 95% of people. It is given by injection into a vein.


Eflornithine, sold under the brand name Vaniqa among others, is a medication used to treat African trypanosomiasis and excessive hair growth on the face in women. Specifically it is used for the 2nd stage of sleeping sickness caused by T. b. gambiense and may be used with nifurtimox. It is used by injection or applied to the skin.

David Bruce (microbiologist) British pathologist

Major-General Sir David Bruce was an Australian-born British pathologist and microbiologist who made some of the key contributions in tropical medicine. In 1887, he discovered a bacterium, now called Brucella, that caused what was known as Malta fever. In 1894, he discovered a protozoan parasite, named Trypanosoma brucei, as the causative pathogen of nagana.

Animal trypanosomiasis

Animal trypanosomiasis, also known as nagana and nagana pest, or sleeping sickness, is a disease of vertebrates. The disease is caused by trypanosomes of several species in the genus Trypanosoma such as Trypanosoma brucei. Trypanosoma vivax causes nagana mainly in West Africa, although it has spread to South America. The trypanosomes infect the blood of the vertebrate host, causing fever, weakness, and lethargy, which lead to weight loss and anemia; in some animals the disease is fatal unless treated. The trypanosomes are transmitted by tsetse flies.

Winterbottom's sign is a swelling of lymph nodes (lymphadenopathy) along the posterior cervical lymph node chain, associated with the early phase of African trypanosomiasis, a disease caused by the parasites Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. It may be suggestive of cerebral infection. Winterbottom reported about the slave traders who, apparently aware of the ominous sign of swollen cervical lymph glands, used to palpate the necks of the slaves before buying them.

Apolipoprotein L1

Apolipoprotein L1 is a protein that in humans is encoded by the APOL1 gene. Two transcript variants encoding two different isoforms have been found for this gene.

<i>Trypanosoma congolense</i>

Trypanosoma congolense is a species of trypanosomes and is the major pathogen responsible for the disease nagana in cattle and other animals including sheep, pigs, goats, horses and camels, dogs, as well as laboratory mice. It is the most common cause of nagana in east Africa, but is also a major cause of nagana in west Africa. This parasite is spread by tsetse flies. In its mammalian host, Trypanosoma congolense only lives in blood vessels, and causes in particular anaemia.

Wendy Gibson is Professor of Protozoology at University of Bristol, specialising in trypanosomes and molecular parasitology.

Fexinidazole is a medication used to treat African trypanosomiasis caused by Trypanosoma brucei gambiense. It is effective against both first and second stage disease. Some evidence also supports its use in Chagas disease. It is taken by mouth.

Variant surface glycoprotein

Variant surface glycoprotein (VSG) is a ~60kDa protein which densely packs the cell surface of protozoan parasites belonging to the genus Trypanosoma. This genus is notable for their cell surface proteins. They were first isolated from Trypanosoma brucei in 1975 by George Cross. VSG allows the trypanosomatid parasites to evade the mammalian host's immune system by extensive antigenic variation. They form a 12–15 nm surface coat. VSG dimers, ~90% of all cell surface protein. It also makes up ~10% of total cell protein. For this reason, these proteins are highly immunogenic and an immune response raised against a specific VSG coat will rapidly kill trypanosomes expressing this variant. However, with each cell division there is a possibility that the progeny will switch expression to change the VSG that is being expressed. VSG has no prescribed biochemical activity.

John William Watson Stephens

John William Watson Stephens FRS (1865–1946) was a British parasitologist and expert on tropical diseases.

Robert Michael Forde

Robert Michael Forde was Colonial Surgeon in The Gambia when in 1901, he made the first definitive observation of trypanosomes in a human being when he found them in the blood of a steamboat master on the Gambia River. In 1907 he became principal medical officer of Sierra Leone.

The Sleeping Sickness Commission was a medical project established by the British Royal Society to investigate the outbreak of African sleeping sickness or African trypanosomiasis in Africa at the turn of the 20th century. The outbreak of the disease started in 1900 in Uganda, which was at the time a protectorate of the British Empire. The initial team in 1902 consisted of Aldo Castellani and George Carmichael Low, both from the London School of Hygiene and Tropical Medicine, and Cuthbert Christy, a medical officer on duty in Bombay, India. From 1903, David Bruce of the Royal Army Medical Corps and David Nunes Nabarro of the University College Hospital took over the leadership. The commission established that species of blood protozoan called Trypanosoma brucei, named after Bruce, was the causative parasite of sleeping sickness.


  1. 1 2 3 4 5 6 7 8 9 10 Luzak, Vanessa; López-Escobar, Lara; Siegel, T. Nicolai; Figueiredo, Luisa M. (8 October 2021). "Cell-to-Cell Heterogeneity in Trypanosomes". Annual Review of Microbiology . Annual Reviews. 75 (1): 107–128. doi:10.1146/annurev-micro-040821-012953. ISSN   0066-4227.
  2. Baker JR (March 1995). "The subspecific taxonomy of Trypanosoma brucei". Parasite. 2 (1): 3–12. doi:10.1051/parasite/1995021003. PMID   9137639. Open Access logo PLoS transparent.svg
  3. Deborggraeve S, Koffi M, Jamonneau V, Bonsu FA, Queyson R, Simarro PP, Herdewijn P, Büscher P (August 2008). "Molecular analysis of archived blood slides reveals an atypical human Trypanosoma infection". Diagnostic Microbiology and Infectious Disease. 61 (4): 428–33. doi:10.1016/j.diagmicrobio.2008.03.006. PMID   18455900.
  4. Masocha W, Kristensson K (2012). "Passage of parasites across the blood-brain barrier". Virulence. 3 (2): 202–12. doi:10.4161/viru.19178. PMC   3396699 . PMID   22460639.
  5. Legros D, Ollivier G, Gastellu-Etchegorry M, Paquet C, Burri C, Jannin J, Büscher P (July 2002). "Treatment of human African trypanosomiasis—present situation and needs for research and development". The Lancet. Infectious Diseases. 2 (7): 437–40. doi:10.1016/S1473-3099(02)00321-3. hdl: 10144/18268 . PMID   12127356.
  6. Gibson W (July 2007). "Resolution of the species problem in African trypanosomes". International Journal for Parasitology. 37 (8–9): 829–38. doi:10.1016/j.ijpara.2007.03.002. PMID   17451719.
  7. Joubert JJ, Schutte CH, Irons DJ, Fripp PJ (1993). "Ubombo and the site of David Bruce's discovery of Trypanosoma brucei". Transactions of the Royal Society of Tropical Medicine and Hygiene. 87 (4): 494–5. doi:10.1016/0035-9203(93)90056-v. PMID   8249096.
  8. Cook GC (1994). "Sir David Bruce's elucidation of the aetiology of nagana--exactly one hundred years ago". Transactions of the Royal Society of Tropical Medicine and Hygiene. 88 (3): 257–8. doi: 10.1016/0035-9203(94)90068-x . PMID   7974656.
  9. 1 2 Steverding, Dietmar (2008). "The history of African trypanosomiasis". Parasites & Vectors. 1 (1): 3. doi:10.1186/1756-3305-1-3. PMC   2270819 . PMID   18275594.
  10. 1 2 Berrang-Ford, Lea; Odiit, Martin; Maiso, Faustin; Waltner-Toews, David; McDermott, John (2006). "Sleeping sickness in Uganda: revisiting current and historical distributions". African Health Sciences. 6 (4): 223–231. PMC   1832067 . PMID   17604511.
  11. Mullen, Gary R.; Durden, Lance A. (2009). Medical and Veterinary Entomology (2 ed.). Academic Press. p. 297. ISBN   978-0-08-091969-0.
  12. Bruce, David (1895). Preliminary Report on the Tsetse Fly Disease or Nagana, in Zululand. Durban (South Africa): Bennett & Davis. p. 1.
  13. 1 2 Donelson, Linda G.; Donelson, John E. (1 February 2008). "The fatal sleep: Africa's killer disease that went undiscovered for centuries". The Journal of Clinical Investigation. 118 (2): 393. doi:10.1172/JCI34802. PMC   2214720 .
  14. Cox, Francis E. G. (2004). "History of sleeping sickness (African trypanosomiasis)". Infectious Disease Clinics. 18 (2): 231–245. doi:10.1016/j.idc.2004.01.004. PMID   15145378.
  15. Ormerod, W. E. (1991). "Hypothesis: the significance of Winterbottom's sign". The Journal of Tropical Medicine and Hygiene. 94 (5): 338–340. ISSN   0022-5304. PMID   1942213.
  16. Cook, G.C. (2007). Tropical Medicine: An Illustrated History of The Pioneers. Burlington (US): Elsevier Ltd. pp. 145–156. ISBN   978-0-08-055939-1.
  17. Ellis, H. (March 2006). "Sir David Bruce, a pioneer of tropical medicine". British Journal of Hospital Medicine. 67 (3): 158. doi:10.12968/hmed.2006.67.3.20624. PMID   16562450.
  18. Martini, Erich (1903). "Ueber die Entwickelung der Tsetseparasiten in Säugethieren" [Preliminary note on the morphology and distribution of the parasite found in tsetse disease]. Zeitschrift für Hygiene und Infektionskrankheiten (in German). 42 (1): 341–351. doi:10.1007/BF02217469. S2CID   12816407.
  19. Novy, Frederick G. (1907). "Trypanosomes". Journal of the American Medical Association. XLVIII (1): 1–10. doi:10.1001/jama.1907.25220270001001.
  20. Steverding, Dietmar (2008). "The history of African trypanosomiasis". Parasites & Vectors. 1 (1): 3. doi:10.1186/1756-3305-1-3. PMC   2270819 . PMID   18275594.
  21. Cox, Francis E. G. (2004). "History of sleeping sickness (African trypanosomiasis)". Infectious Disease Clinics. 18 (2): 231–245. doi:10.1016/j.idc.2004.01.004. PMID   15145378.
  22. Dutton, J. E. (1902). "Preliminary note upon a trypanosome occurring in the blood of man". Wellcome Collection. Retrieved 21 March 2021.{{cite web}}: CS1 maint: url-status (link)
  23. 1 2 Fèvre, E. M.; Coleman, P. G.; Welburn, S. C.; Maudlin, I. (2004). "Reanalyzing the 1900-1920 sleeping sickness epidemic in Uganda". Emerging Infectious Diseases. 10 (4): 567–573. doi: 10.3201/eid1004.020626 . PMID   15200843.
  24. Cook, Gordon (2007). Tropical Medicine: An Illustrated History of The Pioneers. London: Elsevier. pp. 133–135. ISBN   978-0-08-055939-1.
  25. Mott, F. W. (1899). "The Changes in the Central Nervous System of Two Cases of Negro Lethargy: Sequel to Dr. Manson's Clinical Report". British Medical Journal. 2 (2033): 1666–1669. doi:10.1136/bmj.2.2033.1666. PMC   2412509 . PMID   20758763.
  26. Cook, G. C. (1996). "The 'Negro lethargy' in Uganda". Parasitology Today. 12 (1): 41. doi:10.1016/0169-4758(96)90083-6. ISSN   0169-4758. PMID   15275309.
  27. Castellani, Aldo. (1903). "The history of the association of Trypanosoma with sleeping sickness". British Medical Journal. 2 (2241): 1565. PMC   2514975 .
  28. Köhler, Werner; Köhler, Michael (2002). "Zentralblatt für Bakteriologie--100 years ago: sleeping sickness--intoxication or infectious disease?". International Journal of Medical Microbiology. 292 (3–4): 141–147. doi:10.1078/1438-4221-00190. PMID   12398205.
  29. Boyd, J. (1973). "Sleeping sickness. The Castellani-Bruce controversy". Notes and Records of the Royal Society of London. 28: 93–110. doi:10.1098/rsnr.1973.0008. PMID   11615538. S2CID   37631020.
  30. Cook, G. C. (1993). "George Carmichael Low FRCP: an underrated figure in British tropical medicine". Journal of the Royal College of Physicians of London. 27 (1): 81–82. PMC   5396591 . PMID   8426352.
  31. Cook, G.C. (1993). "George Carmichael Low FRCP: twelfth President of the Society and underrated pioneer of tropical medicine". Transactions of the Royal Society of Tropical Medicine and Hygiene. 87 (4): 355–360. doi:10.1016/0035-9203(93)90002-8. PMID   8249057.
  32. Amaral, Isabel (2012). "Bacteria or parasite? the controversy over the etiology of sleeping sickness and the Portuguese participation, 1898-1904". História, Ciências, Saúde-Manguinhos. 19 (4): 1275–1300. doi: 10.1590/s0104-59702012005000004 . PMID   23184240.
  33. Cook, G. C. (2012). "Patrick Manson (1844-1922) FRS: Filaria (Mansonella) perstans and sleeping sickness (African trypanosomiasis)". Journal of Medical Biography. 20 (2): 69. doi:10.1258/jmb.2010.010051. PMID   22791871. S2CID   33661530.
  34. Lumsden, W. H. (1974). "Some episodes in the history of African trypanosomiasis". Proceedings of the Royal Society of Medicine. 67 (8): 789–796. doi:10.1177/003591577406700846. PMC   1645813 . PMID   4607392.
  35. Lumsden, W. H. (1974). "Some episodes in the history of African trypanosomiasis". Proceedings of the Royal Society of Medicine. 67 (8): 789–796. doi:10.1177/003591577406700846. PMC   1645813 . PMID   4607392.
  36. Wiggins, C. A. (1960). "Early days in East Africa and Uganda". East African Medical Journal. 37: 699–708. PMID   13785176.
  37. Cook, Gordon (2007). Tropical Medicine: An Illustrated History of The Pioneers. London: Elsevier. pp. 133–135. ISBN   978-0-08-055939-1.
  38. Davies, J. N. (1962). "The cause of sleeping-sickness? Entebbe 1902-03. I". East African Medical Journal. 39: 81–99. PMID   13883839.
  39. J.R. B. (1932). "Sir David Bruce. 1855-1931". Obituary Notices of Fellows of the Royal Society. 1 (1): 79–85. doi:10.1098/rsbm.1932.0017. ISSN   1479-571X. JSTOR   768965.
  40. Lumsden, W. H. (1974). "Some episodes in the history of African trypanosomiasis". Proceedings of the Royal Society of Medicine. 67 (8): 789–796. doi:10.1177/003591577406700846. PMC   1645813 . PMID   4607392.
  41. Boyd, J. (1973). "Sleeping sickness. The Castellani-Bruce controversy". Notes and Records of the Royal Society of London. 28: 93–110. doi:10.1098/rsnr.1973.0008. PMID   11615538. S2CID   37631020.
  42. Castellani, Aldo (1903). "On the discovery of a species of trypanosoma in the cerebrospinal fluid of cases of sleeping sickness". The Lancet. 161 (4164): 1735–1736. doi:10.1016/S0140-6736(01)70338-8.
  43. Castellani, Also (1903). "On the discovery of a species of trypanosoma in the cerebrospinal fluid of cases of sleeping sickness". Proceedings of the Royal Society of London. 71 (467–476): 501–508. doi:10.1098/rspl.1902.0134.
  44. Welburn, S. C.; Maudlin, I.; Simarro, P. P. (2009). "Controlling sleeping sickness - a review". Parasitology. 136 (14): 1943–1949. doi:10.1017/S0031182009006416. PMID   19691861.
  45. 1 2 Steverding, Dietmar (2008). "The history of African trypanosomiasis". Parasites & Vectors. 1 (1): 3. doi:10.1186/1756-3305-1-3. PMC   2270819 . PMID   18275594.
  46. Bruce, David; Hamerton, A. E.; Bateman, H. R.; Mackie, F. P. (1909). "The development of Trypanosoma gambiense in Glossina palpalis". Proceedings of the Royal Society of London. Series B. 81 (550): 405–414. doi:10.1098/rspb.1909.0041.
  47. Bruce, David; Hamerton, A. E.; Bateman, H. R.; Mackie, F. P. (1911). "Further researches on the development of Trypanosoma gambiense in Glossina palpalis". Proceedings of the Royal Society of London. Series B. 83 (567): 513–527. doi:10.1098/rspb.1911.0034.
  48. Stephens, John William Watson; Fantham, H. B.; Ross, Ronald (1910). "On the peculiar morphology of a trypanosome from a case of sleeping sickness and the possibility of its being a new species (T. rhodesiense)". Proceedings of the Royal Society of London. Series B. 83 (561): 28–33. doi:10.1098/rspb.1910.0064.
  49. Stephens, J. W. W.; Fantham, H. B. (1910). "On the Peculiar Morphology of a Trypanosome From a Case of Sleeping Sickness and the Possibility of Its Being a New Species (T. Rhodesiense)". Annals of Tropical Medicine & Parasitology. 4 (3): 343–350. doi:10.1080/00034983.1910.11685723.
  50. 1 2 Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, Krishna S (November 2003). "The trypanosomiases". Lancet. 362 (9394): 1469–80. doi:10.1016/S0140-6736(03)14694-6. PMID   14602444. S2CID   7917540.
  51. Molyneux, David Hurst (1973). "Animal reservoirs and Gambian trypanosomiasis". Annales de la Société Belge de Médecine Tropicale. 53 (6): 605–618. ISSN   0772-4128. PMID   4204667.
  52. 1 2 Büscher, Philippe; Cecchi, Giuliano; Jamonneau, Vincent; Priotto, Gerardo (2017). "Human African trypanosomiasis". Lancet. 390 (10110): 2397–2409. doi:10.1016/S0140-6736(17)31510-6. PMID   28673422.
  53. Stephens NA, Kieft R, Macleod A, Hajduk SL (December 2012). "Trypanosome resistance to human innate immunity: targeting Achilles' heel". Trends in Parasitology. 28 (12): 539–45. doi:10.1016/ PMC   4687903 . PMID   23059119.
  54. Rifkin, M.R. (1984). "Trypanosoma brucei: Biochemical and morphological studies of cytotoxicity caused by normal human serum". Experimental Parasitology . Elsevier. 58 (1): 81–93. doi:10.1016/0014-4894(84)90023-7. ISSN   0014-4894. PMID   6745390.
  55. Balmer, Oliver; Beadell, Jon S.; Gibson, Wendy; Caccone, Adalgisa (8 February 2011). "Phylogeography and Taxonomy of Trypanosoma brucei". PLoS Neglected Tropical Diseases. 5 (2): e961. doi:10.1371/journal.pntd.0000961. PMC   3035665 . PMID   21347445.
  56. Amodeo, Simona; Jakob, Martin; Ochsenreiter, Torsten (6 April 2018). "Characterization of the novel mitochondrial genome replication factor MiRF172 in Trypanosoma brucei". Journal of Cell Science . The Company of Biologists. 131 (8): jcs211730. doi: 10.1242/jcs.211730 . ISSN   0021-9533. PMC   5963845 . PMID   29626111.
  57. 1 2 3 4 "African animal trypanosomes". Food and Agricultural Organization. Retrieved 28 January 2016.
  58. Romero-Meza, Gabriela; Mugnier, Monica R. (2020). "Trypanosoma brucei". Trends in Parasitology. 36 (6): 571–572. doi:10.1016/ PMC   7375462 . PMID   31757771.
  59. Koyfman, Alexey Y.; Schmid, Michael F.; Gheiratmand, Ladan; Fu, Caroline J.; Khant, Htet A.; Huang, Dandan; He, Cynthia Y.; Chiu, Wah (2011). "Structure of Trypanosoma brucei flagellum accounts for its bihelical motion". Proceedings of the National Academy of Sciences of the United States of America. 108 (27): 11105–11108. doi:10.1073/pnas.1103634108. PMC   3131312 . PMID   21690369.
  60. Cachon, Jean; Cachon, Monique; Cosson, Marie-Paule; Cosson, Jacky (1988). "The paraflagellar rod: a structure in search of a function". Biology of the Cell. 63 (2): 169–181. doi:10.1016/0248-4900(88)90056-1. ISSN   0248-4900. S2CID   86009836. Alternate access through Science Direct: 0248490088900561
  61. Bastin, P.; Matthews, K. R.; Gull, K. (1996). "The paraflagellar rod of kinetoplastida: solved and unsolved questions". Parasitology Today. 12 (8): 302–307. doi:10.1016/0169-4758(96)10031-4. PMID   15275181.
  62. Sunter, Jack D.; Gull, Keith (2016). "The Flagellum Attachment Zone: 'The Cellular Ruler' of Trypanosome Morphology". Trends in Parasitology . Cell Press. 32 (4): 309–324. doi:10.1016/ ISSN   1471-4922. PMC   4827413 . PMID   26776656. S2CID   1080165.
  63. Woods, A.; Sherwin, T.; Sasse, R.; MacRae, T. H.; Baines, A. J.; Gull, K. (1989). "Definition of individual components within the cytoskeleton of Trypanosoma brucei by a library of monoclonal antibodies". Journal of Cell Science. 93 ( Pt 3): 491–500. doi:10.1242/jcs.93.3.491. PMID   2606940.
  64. 1 2 Langousis G, Hill KL (July 2014). "Motility and more: the flagellum of Trypanosoma brucei". Nature Reviews. Microbiology. 12 (7): 505–18. doi:10.1038/nrmicro3274. PMC   4278896 . PMID   24931043.
  65. Halliday, Clare; de Castro-Neto, Artur; Alcantara, Carolina L.; Cunha-E-Silva, Narcisa L.; Vaughan, Sue; Sunter, Jack D. (2021). "Trypanosomatid Flagellar Pocket from Structure to Function". Trends in Parasitology. 37 (4): 317–329. doi:10.1016/ PMID   33308952.
  66. 1 2 Juan, Thomas; Fürthauer, Maximilian (2018). "Biogenesis and function of ESCRT-dependent extracellular vesicles". Seminars in Cell & Developmental Biology . Elsevier. 74: 66–77. doi:10.1016/j.semcdb.2017.08.022. ISSN   1084-9521.
  67. 1 2 3 4 Chatterjee, K.D. (2009). Parasitology (Protozoology and Helminthology) in relation to clinical medicine (13 ed.). New Delhi: CBC Publishers. pp. 56–57. ISBN   978-8-12-39-1810-5.
  68. 1 2 "Parasites - African Trypanosomiasis (also known as Sleeping Sickness)". Centers for Disease Control and Prevention. Retrieved 29 January 2016.
  69. 1 2 3 4 Seed, John; Wenck, Mary (2003). "Role of the long slender to short stumpy transition in the life cycle of the african trypanosomes". Kinetoplastid Biology and Disease . BioMed Central. 2 (1): 3. doi:10.1186/1475-9292-2-3. ISSN   1475-9292.
  70. 1 2 Mideo, Nicole; Acosta-Serrano, Alvaro; Aebischer, Toni; Brown, Mark J. F.; Fenton, Andy; Friman, Ville-Petri; Restif, Olivier; Reece, Sarah E.; Webster, Joanne P.; Brown, Sam P. (2013). "Life in cells, hosts, and vectors: Parasite evolution across scales". Infection, Genetics and Evolution. 13: 344–347. doi:10.1016/j.meegid.2012.03.016. PMID   22465537.(VPF ORCID 0000-0002-1592-157X).
  71. Lefèvre, T.; Thomas, F.; Ravel, S.; Patrel, D.; Renault, L.; Le Bourligu, L.; Cuny, G.; Biron, D. G. (17 December 2007). "Trypanosoma brucei brucei induces alteration in the head proteome of the tsetse fly vector Glossina palpalis gambiensis". Insect Molecular Biology . Royal Entomological Society (Wiley). 16 (6): 651–660. doi:10.1111/j.1365-2583.2007.00761.x. ISSN   0962-1075. PMID   18092995. S2CID   3134104.
  72. Zampetti-Bosseler F, Schweizer J, Pays E, Jenni L, Steinert M (August 1986). "Evidence for haploidy in metacyclic forms of Trypanosoma brucei". Proceedings of the National Academy of Sciences of the United States of America. 83 (16): 6063–4. Bibcode:1986PNAS...83.6063Z. doi: 10.1073/pnas.83.16.6063 . PMC   386438 . PMID   3461475.
  73. Jenni L (1990). "Sexual stages in trypanosomes and implications". Annales de Parasitologie Humaine et Comparée. 65 Suppl 1: 19–21. doi: 10.1051/parasite/1990651019 . PMID   2264676.
  74. Peacock L, Ferris V, Sharma R, Sunter J, Bailey M, Carrington M, Gibson W (March 2011). "Identification of the meiotic life cycle stage of Trypanosoma brucei in the tsetse fly". Proceedings of the National Academy of Sciences of the United States of America. 108 (9): 3671–6. Bibcode:2011PNAS..108.3671P. doi: 10.1073/pnas.1019423108 . PMC   3048101 . PMID   21321215.
  75. Peacock L, Bailey M, Carrington M, Gibson W (January 2014). "Meiosis and haploid gametes in the pathogen Trypanosoma brucei". Current Biology. 24 (2): 181–6. doi:10.1016/j.cub.2013.11.044. PMC   3928991 . PMID   24388851.
  76. Peacock L, Ferris V, Bailey M, Gibson W (February 2014). "Mating compatibility in the parasitic protist Trypanosoma brucei". Parasites & Vectors. 7 (1): 78. doi:10.1186/1756-3305-7-78. PMC   3936861 . PMID   24559099.
  77. Hampl V, Hug L, Leigh JW, Dacks JB, Lang BF, Simpson AG, Roger AJ (March 2009). "Phylogenomic analyses support the monophyly of Excavata and resolve relationships among eukaryotic "supergroups"". Proceedings of the National Academy of Sciences of the United States of America. 106 (10): 3859–64. Bibcode:2009PNAS..106.3859H. doi: 10.1073/pnas.0807880106 . PMC   2656170 . PMID   19237557.
  78. Malik SB, Pightling AW, Stefaniak LM, Schurko AM, Logsdon JM (August 2007). "An expanded inventory of conserved meiotic genes provides evidence for sex in Trichomonas vaginalis". PLOS ONE. 3 (8): e2879. Bibcode:2008PLoSO...3.2879M. doi: 10.1371/journal.pone.0002879 . PMC   2488364 . PMID   18663385.
  79. Krisnky WL (2009). "Tsetse fly (Glossinidae)". In Mullen GR, Durden L (eds.). Medical and Veterinary Entomology (2 ed.). Amsterdam: Elsevier. p. 296. ISBN   978-0-0-80-91969-0.
  80. "African Trypanosomes: epidemiology and risk factors". Centers for Disease Control. 2 May 2017.
  81. Rocha G, Martins A, Gama G, Brandão F, Atouguia J (January 2004). "Possible cases of sexual and congenital transmission of sleeping sickness". Lancet. 363 (9404): 247. doi:10.1016/S0140-6736(03)15345-7. PMID   14738812. S2CID   5311361.
  82. 1 2 3 Ibrahim, Mohammed Auwal; Mohammed, Aminu; Isah, Murtala Bindawa; Aliyu, Abubakar Babando (2014). "Anti-trypanosomal activity of African medicinal plants: A review update". Journal of Ethnopharmacology . International Society of Ethnopharmacology (Elsevier). 154 (1): 26–54. doi:10.1016/j.jep.2014.04.012. ISSN   0378-8741.
  83. 1 2 Auty, H.; Torr, S.; Michoel, T.; Jayaraman, S.; Morrison, L. (1 August 2015). "Cattle trypanosomosis: the diversity of trypanosomes and implications for disease epidemiology and control". Revue Scientifique et Technique de l'OIE . O.I.E (World Organisation for Animal Health). 34 (2): 587–598. doi:10.20506/rst.34.2.2382. ISSN   0253-1933. PMID   26601459. S2CID   42700199.
  84. 1 2 Weir W, Capewell P, Foth B, Clucas C, Pountain A, Steketee P, Veitch N, Koffi M, De Meeûs T, Kaboré J, Camara M, Cooper A, Tait A, Jamonneau V, Bucheton B, Berriman M, MacLeod A (January 2016). "Population genomics reveals the origin and asexual evolution of human infective trypanosomes". eLife . 5: e11473. doi:10.7554/eLife.11473. PMC   4739771 . PMID   26809473.
  85. Paindavoine P, Pays E, Laurent M, Geltmeyer Y, Le Ray D, Mehlitz D, Steinert M (February 1986). "The use of DNA hybridization and numerical taxonomy in determining relationships between Trypanosoma brucei stocks and subspecies". Parasitology. 92 (Pt 1): 31–50. doi:10.1017/S0031182000063435. PMID   3960593.
  86. Capewell P, Veitch NJ, Turner CM, Raper J, Berriman M, Hajduk SL, MacLeod A (September 2011). "Differences between Trypanosoma brucei gambiense groups 1 and 2 in their resistance to killing by trypanolytic factor 1". PLOS Neglected Tropical Diseases. 5 (9): e1287. doi:10.1371/journal.pntd.0001287. PMC   3167774 . PMID   21909441.
  87. 1 2 Lecordier L, Vanhollebeke B, Poelvoorde P, Tebabi P, Paturiaux-Hanocq F, Andris F, Lins L, Pays E (December 2009). Mansfield JM (ed.). "C-terminal mutants of apolipoprotein L-I efficiently kill both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense". PLOS Pathogens. 5 (12): e1000685. doi:10.1371/journal.ppat.1000685. PMC   2778949 . PMID   19997494.
  88. De Greef C, Imberechts H, Matthyssens G, Van Meirvenne N, Hamers R (September 1989). "A gene expressed only in serum-resistant variants of Trypanosoma brucei rhodesiense". Molecular and Biochemical Parasitology. 36 (2): 169–76. doi:10.1016/0166-6851(89)90189-8. PMID   2528066.
  89. Ogbadoyi E, Ersfeld K, Robinson D, Sherwin T, Gull K (March 2000). "Architecture of the Trypanosoma brucei nucleus during interphase and mitosis". Chromosoma. 108 (8): 501–13. doi:10.1007/s004120050402. PMID   10794572. S2CID   3850480.
  90. Jackson, Andrew P.; Sanders, Mandy; Berry, Andrew; McQuillan, Jacqueline; Aslett, Martin A.; Quail, Michael A.; Chukualim, Bridget; Capewell, Paul; MacLeod, Annette; Melville, Sara E.; Gibson, Wendy (2010). "The Genome Sequence of Trypanosoma brucei gambiense, Causative Agent of Chronic Human African Trypanosomiasis". PLoS Neglected Tropical Diseases. 4 (4): e658. doi:10.1371/journal.pntd.0000658. PMC   2854126 . PMID   20404998.
  91. Ogbadoyi, Emmanuel O.; Robinson, Derrick R.; Gull, Keith (2003). "A High-Order Trans-Membrane Structural Linkage Is Responsible for Mitochondrial Genome Positioning and Segregation by Flagellar Basal Bodies in Trypanosomes". Molecular Biology of the Cell. 14 (5): 1769–1779. doi:10.1091/mbc.E02-08-0525. PMC   165075 . PMID   12802053.
  92. Borst P, Sabatini R (2008). "Base J: discovery, biosynthesis, and possible functions". Annual Review of Microbiology. 62: 235–51. doi:10.1146/annurev.micro.62.081307.162750. PMID   18729733.
  93. 1 2 Barry JD, McCulloch R (2001). "Antigenic variation in trypanosomes: enhanced phenotypic variation in a eukaryotic parasite". Advances in Parasitology Volume 49. Advances in Parasitology. Vol. 49. pp. 1–70. doi:10.1016/S0065-308X(01)49037-3. ISBN   978-0-12-031749-3. PMID   11461029.
  94. Barry JD, McCulloch R (2001). "Antigenic variation in trypanosomes: enhanced phenotypic variation in a eukaryotic parasite". Advances in Parasitology Volume 49. Advances in Parasitology. Vol. 49. pp. 1–70. doi:10.1016/S0065-308X(01)49037-3. ISBN   978-0-12-031749-3. PMID   11461029.
  95. 1 2 Morrison LJ, Marcello L, McCulloch R (December 2009). "Antigenic variation in the African trypanosome: molecular mechanisms and phenotypic complexity" (PDF). Cellular Microbiology. 11 (12): 1724–34. doi:10.1111/j.1462-5822.2009.01383.x. PMID   19751359. S2CID   26552797.
  96. Turner CM (August 1997). "The rate of antigenic variation in fly-transmitted and syringe-passaged infections of Trypanosoma brucei". FEMS Microbiology Letters. 153 (1): 227–31. doi:10.1111/j.1574-6968.1997.tb10486.x. PMID   9252591.
  97. Barry JD, Hall JP, Plenderleith L (September 2012). "Genome hyperevolution and the success of a parasite". Annals of the New York Academy of Sciences. 1267 (1): 11–7. Bibcode:2012NYASA1267...11B. doi:10.1111/j.1749-6632.2012.06654.x. PMC   3467770 . PMID   22954210.
  98. Hall JP, Wang H, Barry JD (11 July 2013). "Mosaic VSGs and the scale of Trypanosoma brucei antigenic variation". PLOS Pathogens. 9 (7): e1003502. doi:10.1371/journal.ppat.1003502. PMC   3708902 . PMID   23853603.
  99. Mugnier MR, Cross GA, Papavasiliou FN (March 2015). "The in vivo dynamics of antigenic variation in Trypanosoma brucei". Science. 347 (6229): 1470–3. Bibcode:2015Sci...347.1470M. doi:10.1126/science.aaa4502. PMC   4514441 . PMID   25814582.
  100. Pays E (November 2005). "Regulation of antigen gene expression in Trypanosoma brucei". Trends in Parasitology. 21 (11): 517–20. doi:10.1016/ PMID   16126458.
  101. Rudenko, Gloria (26 October 2018). "Faculty of 1000 evaluation for Genome organization and DNA accessibility control antigenic variation in trypanosomes". F1000 . doi: 10.3410/f.734240334.793552268 .
  102. Müller, Laura S. M.; Cosentino, Raúl O.; Förstner, Konrad U.; Guizetti, Julien; Wedel, Carolin; Kaplan, Noam; Janzen, Christian J.; Arampatzi, Panagiota; Vogel, Jörg; Steinbiss, Sascha; Otto, Thomas D.; Saliba, Antoine-Emmanuel; Sebra, Robert P.; Siegel, T. Nicolai (17 October 2018). "Genome organization and DNA accessibility control antigenic variation in trypanosomes". Nature . Nature Research. 563 (7729): 121–125. Bibcode:2018Natur.563..121M. doi: 10.1038/s41586-018-0619-8 . ISSN   0028-0836. PMC   6784898 . PMID   30333624.
  103. Hajduk SL, Moore DR, Vasudevacharya J, Siqueira H, Torri AF, Tytler EM, Esko JD (March 1989). "Lysis of Trypanosoma brucei by a toxic subspecies of human high density lipoprotein". The Journal of Biological Chemistry. 264 (9): 5210–7. doi: 10.1016/S0021-9258(18)83720-6 . PMID   2494183.
  104. Raper J, Fung R, Ghiso J, Nussenzweig V, Tomlinson S (April 1999). "Characterization of a novel trypanosome lytic factor from human serum". Infection and Immunity. 67 (4): 1910–6. doi:10.1128/IAI.67.4.1910-1916.1999. PMC   96545 . PMID   10085035.
  105. Vanhollebeke, Benoit; Pays, Etienne (2010). "The trypanolytic factor of human serum: many ways to enter the parasite, a single way to kill". Molecular Microbiology. 76 (4): 806–814. doi:10.1111/j.1365-2958.2010.07156.x. PMID   20398209.
  106. Lugli EB, Pouliot M, del Portela M, Loomis MR, Raper J (November 2004). "Characterization of primate trypanosome lytic factors". Molecular and Biochemical Parasitology. 138 (1): 9–20. doi:10.1016/j.molbiopara.2004.07.004. PMID   15500911.
  107. Vanhollebeke B, Pays E (September 2006). "The function of apolipoproteins L". Cellular and Molecular Life Sciences. 63 (17): 1937–44. doi:10.1007/s00018-006-6091-x. PMID   16847577. S2CID   12713960.
  108. 1 2 3 4 Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan DP, Lins L, Van Den Abbeele J, Pays A, Tebabi P, Van Xong H, Jacquet A, Moguilevsky N, Dieu M, Kane JP, De Baetselier P, Brasseur R, Pays E (March 2003). "Apolipoprotein L-I is the trypanosome lytic factor of human serum". Nature. 422 (6927): 83–7. Bibcode:2003Natur.422...83V. doi:10.1038/nature01461. PMID   12621437. S2CID   4310920.
  109. Smith EE, Malik HS (May 2009). "The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions". Genome Research. 19 (5): 850–8. doi:10.1101/gr.085647.108. PMC   2675973 . PMID   19299565.
  110. 1 2 3 Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR (August 2010). "Association of trypanolytic ApoL1 variants with kidney disease in African Americans". Science. 329 (5993): 841–5. Bibcode:2010Sci...329..841G. doi:10.1126/science.1193032. PMC   2980843 . PMID   20647424.
  111. Wasser WG, Tzur S, Wolday D, Adu D, Baumstein D, Rosset S, Skorecki K (2012). "Population genetics of chronic kidney disease: the evolving story of APOL1". Journal of Nephrology. 25 (5): 603–18. doi:10.5301/jn.5000179. PMID   22878977.
  112. Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, Astor BC, Bottinger EP, Iyengar SK, Klotman PE, Freedman RG, Zhang W, Parekh RS, Choi MJ, Nelson GW, Winkler CA, Kopp JB (January 2013). "Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans". Kidney International. 83 (1): 114–20. doi:10.1038/ki.2012.263. PMC   3484228 . PMID   22832513.
  113. Duchateau PN, Pullinger CR, Orellana RE, Kunitake ST, Naya-Vigne J, O'Connor PM, Malloy MJ, Kane JP (October 1997). "Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L". The Journal of Biological Chemistry. 272 (41): 25576–82. doi: 10.1074/jbc.272.41.25576 . PMID   9325276.
  114. Pérez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, Nolan DP, Lins L, Homblé F, Vanhamme L, Tebabi P, Pays A, Poelvoorde P, Jacquet A, Brasseur R, Pays E (July 2005). "Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes". Science. 309 (5733): 469–72. Bibcode:2005Sci...309..469P. doi:10.1126/science.1114566. PMID   16020735. S2CID   33189804.
  115. Madhavan SM, O'Toole JF, Konieczkowski M, Ganesan S, Bruggeman LA, Sedor JR (November 2011). "APOL1 localization in normal kidney and nondiabetic kidney disease". Journal of the American Society of Nephrology. 22 (11): 2119–28. doi:10.1681/ASN.2011010069. PMC   3231786 . PMID   21997392.
  116. Zhaorigetu S, Wan G, Kaini R, Jiang Z, Hu CA (November 2008). "ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death". Autophagy. 4 (8): 1079–82. doi:10.4161/auto.7066. PMC   2659410 . PMID   18927493.
  117. Widener, Justin; Nielsen, Marianne Jensby; Shiflett, April; Moestrup, Søren Kragh; Hajduk, Stephen (2007). "Hemoglobin is a co-factor of human trypanosome lytic factor". PLoS Pathogens. 3 (9): 1250–1261. doi:10.1371/journal.ppat.0030129. PMC   1971115 . PMID   17845074.
  118. 1 2 3 Vanhollebeke B, De Muylder G, Nielsen MJ, Pays A, Tebabi P, Dieu M, Raes M, Moestrup SK, Pays E (May 2008). "A haptoglobin-hemoglobin receptor conveys innate immunity to Trypanosoma brucei in humans". Science. 320 (5876): 677–81. Bibcode:2008Sci...320..677V. doi:10.1126/science.1156296. PMID   18451305. S2CID   206512161.
  119. Vanhollebeke B, Nielsen MJ, Watanabe Y, Truc P, Vanhamme L, Nakajima K, Moestrup SK, Pays E (March 2007). "Distinct roles of haptoglobin-related protein and apolipoprotein L-I in trypanolysis by human serum". Proceedings of the National Academy of Sciences of the United States of America. 104 (10): 4118–23. Bibcode:2007PNAS..104.4118V. doi: 10.1073/pnas.0609902104 . PMC   1820718 . PMID   17360487.
  120. Higgins MK, Tkachenko O, Brown A, Reed J, Raper J, Carrington M (January 2013). "Structure of the trypanosome haptoglobin-hemoglobin receptor and implications for nutrient uptake and innate immunity". Proceedings of the National Academy of Sciences of the United States of America. 110 (5): 1905–10. Bibcode:2013PNAS..110.1905H. doi: 10.1073/pnas.1214943110 . PMC   3562850 . PMID   23319650.
  121. Green HP, Del Pilar Molina Portela M, St Jean EN, Lugli EB, Raper J (January 2003). "Evidence for a Trypanosoma brucei lipoprotein scavenger receptor". The Journal of Biological Chemistry. 278 (1): 422–7. doi: 10.1074/jbc.M207215200 . PMID   12401813.
  122. Pays E, Vanhollebeke B, Vanhamme L, Paturiaux-Hanocq F, Nolan DP, Pérez-Morga D (June 2006). "The trypanolytic factor of human serum". Nature Reviews. Microbiology. 4 (6): 477–86. doi:10.1038/nrmicro1428. PMID   16710327. S2CID   6151924.
  123. 1 2 3 Uzureau P, Uzureau S, Lecordier L, Fontaine F, Tebabi P, Homblé F, Grélard A, Zhendre V, Nolan DP, Lins L, Crowet JM, Pays A, Felu C, Poelvoorde P, Vanhollebeke B, Moestrup SK, Lyngsø J, Pedersen JS, Mottram JC, Dufourc EJ, Pérez-Morga D, Pays E (September 2013). "Mechanism of Trypanosoma brucei gambiense resistance to human serum". Nature. 501 (7467): 430–4. Bibcode:2013Natur.501..430U. doi:10.1038/nature12516. PMID   23965626. S2CID   4400057.
  124. DeJesus E, Kieft R, Albright B, Stephens NA, Hajduk SL (2013). "A single amino acid substitution in the group 1 Trypanosoma brucei gambiense haptoglobin-hemoglobin receptor abolishes TLF-1 binding". PLOS Pathogens. 9 (4): e1003317. doi:10.1371/journal.ppat.1003317. PMC   3630162 . PMID   23637606.
  125. Smith, Ann; McCulloh, Russell J. (2015). "Hemopexin and haptoglobin: allies against heme toxicity from hemoglobin not contenders". Frontiers in Physiology. 6: 187. doi:10.3389/fphys.2015.00187. ISSN   1664-042X. PMC   4485156 . PMID   26175690.
  126. Pays E, Vanhollebeke B (July 2008). "Mutual self-defence: the trypanolytic factor story". Microbes and Infection. 10 (9): 985–9. doi:10.1016/j.micinf.2008.07.020. PMID   18675374.
  127. Xong HV, Vanhamme L, Chamekh M, Chimfwembe CE, Van Den Abbeele J, Pays A, Van Meirvenne N, Hamers R, De Baetselier P, Pays E (December 1998). "A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense". Cell. 95 (6): 839–46. doi: 10.1016/S0092-8674(00)81706-7 . PMID   9865701.
  128. Shiflett AM, Faulkner SD, Cotlin LF, Widener J, Stephens N, Hajduk SL (2007). "African trypanosomes: intracellular trafficking of host defense molecules". The Journal of Eukaryotic Microbiology. 54 (1): 18–21. doi:10.1111/j.1550-7408.2006.00228.x. PMID   17300512. S2CID   20054667.
  129. Thomson R, Molina-Portela P, Mott H, Carrington M, Raper J (November 2009). "Hydrodynamic gene delivery of baboon trypanosome lytic factor eliminates both animal and human-infective African trypanosomes". Proceedings of the National Academy of Sciences of the United States of America. 106 (46): 19509–14. Bibcode:2009PNAS..10619509T. doi: 10.1073/pnas.0905669106 . PMC   2780755 . PMID   19858474.
  130. Seed JR, Seed TM, Sechelski J (1978). "The biological effects of tryptophol (indole-3-ethanol): hemolytic, biochemical and behavior modifying activity". Comparative Biochemistry and Physiology C. 60 (2): 175–85. doi:10.1016/0306-4492(78)90091-6. PMID   28889.